NLS Pharmaceutics (NASDAQ:NCEL) Trading 2.2% Higher – Should You Buy?

NLS Pharmaceutics Ltd. (NASDAQ:NCEL) traded up 2.2% during mid-day trading on Wednesday . The stock traded as high as $3.31 and last traded at $3.25. 4,901 shares traded hands during trading, a decline of 93% from the average session volume of 67,647 shares. The stock had previously closed at $3.18.

NLS Pharmaceutics Trading Up 2.2%

The firm’s fifty day moving average is $2.88 and its 200-day moving average is $3.00.

Insider Activity

In other news, Director Olivier Samuel purchased 81,818 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was purchased at an average cost of $2.75 per share, with a total value of $224,999.50. Following the completion of the acquisition, the director directly owned 81,818 shares of the company’s stock, valued at approximately $224,999.50. This trade represents a ? increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Michel Revel purchased 54,545 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average cost of $2.75 per share, with a total value of $149,998.75. Following the completion of the acquisition, the director directly owned 957,530 shares of the company’s stock, valued at $2,633,207.50. This represents a 6.04% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 16.40% of the company’s stock.

About NLS Pharmaceutics

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.